Anzeige
Mehr »
Lynx Broker
Login
Sonntag, 25.08.2019 Börsentäglich über 12.000 News von 607 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Zur alten Webversion

WKN: A0M84G ISIN: SE0002190926 Ticker-Symbol: 2I9 
Frankfurt
22.08.19
08:00 Uhr
0,316 Euro
+0,005
+1,61 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KAROLINSKA DEVELOPMENT AB Chart 1 Jahr
5-Tage-Chart
KAROLINSKA DEVELOPMENT AB 5-Tage-Chart
16.08.2019 | 08:05
(174 Leser)
(1 Bewertungen)

STOCKHOLM, SWEDEN - 16 August 2019. Karolinska Development AB ("Karolinska Development" or the "Company") hereby announces that the Company's Q2 report for the period January - June will be published on 30 August 2019. The previous date of publication was 21 August 2019.

For more information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Fredrik Järrsten, CFO and deputy CEO, Karolinska Development AB
Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com
TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information: www.karolinskadevelopment.com.


Attachment

  • KD Press release - New date for publication of quarterly report (https://ml-eu.globenewswire.com/Resource/Download/d10bdcfd-aaed-403f-ba3c-66c587118212)

© 2019 GlobeNewswire (Europe)